These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 19538097)

  • 1. Kv1.3 potassium channels as a therapeutic target in multiple sclerosis.
    Rangaraju S; Chi V; Pennington MW; Chandy KG
    Expert Opin Ther Targets; 2009 Aug; 13(8):909-24. PubMed ID: 19538097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting effector memory T-cells with Kv1.3 blockers.
    Wulff H; Pennington M
    Curr Opin Drug Discov Devel; 2007 Jul; 10(4):438-45. PubMed ID: 17659485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potassium channels, memory T cells, and multiple sclerosis.
    Beeton C; Chandy KG
    Neuroscientist; 2005 Dec; 11(6):550-62. PubMed ID: 16282596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulatory effects of diclofenac in leukocytes through the targeting of Kv1.3 voltage-dependent potassium channels.
    Villalonga N; David M; Bielańska J; González T; Parra D; Soler C; Comes N; Valenzuela C; Felipe A
    Biochem Pharmacol; 2010 Sep; 80(6):858-66. PubMed ID: 20488163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potassium channels as therapeutic targets for autoimmune disorders.
    Wulff H; Beeton C; Chandy KG
    Curr Opin Drug Discov Devel; 2003 Sep; 6(5):640-7. PubMed ID: 14579513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kv1.3 channel as a promising therapeutic target for acquired aplastic anemia.
    Hu X; Xu C; Cong Y
    Med Hypotheses; 2008; 70(5):1072. PubMed ID: 18158221
    [No Abstract]   [Full Text] [Related]  

  • 7. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases.
    Schmitz A; Sankaranarayanan A; Azam P; Schmidt-Lassen K; Homerick D; Hänsel W; Wulff H
    Mol Pharmacol; 2005 Nov; 68(5):1254-70. PubMed ID: 16099841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting potassium channels Kv1.3 and KC a 3.1: routes to selective immunomodulators in autoimmune disorder treatment?
    Wang J; Xiang M
    Pharmacotherapy; 2013 May; 33(5):515-28. PubMed ID: 23649812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes.
    Hu L; Pennington M; Jiang Q; Whartenby KA; Calabresi PA
    J Immunol; 2007 Oct; 179(7):4563-70. PubMed ID: 17878353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kv1.3 blockers ameliorate allergic contact dermatitis by preferentially suppressing effector memory T cells in a rat model.
    Ueyama A; Imura K; Kasai-Yamamoto E; Tai N; Nagira M; Shichijo M; Yasui K
    Clin Exp Dermatol; 2013 Dec; 38(8):897-903. PubMed ID: 24252082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphocyte activation in type 1 diabetes mellitus: the increased significance of Kv1.3 potassium channels.
    Toldi G; Vásárhelyi B; Kaposi A; Mészáros G; Pánczél P; Hosszufalusi N; Tulassay T; Treszl A
    Immunol Lett; 2010 Sep; 133(1):35-41. PubMed ID: 20603149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases.
    Beeton C; Wulff H; Standifer NE; Azam P; Mullen KM; Pennington MW; Kolski-Andreaco A; Wei E; Grino A; Counts DR; Wang PH; LeeHealey CJ; S Andrews B; Sankaranarayanan A; Homerick D; Roeck WW; Tehranzadeh J; Stanhope KL; Zimin P; Havel PJ; Griffey S; Knaus HG; Nepom GT; Gutman GA; Calabresi PA; Chandy KG
    Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17414-9. PubMed ID: 17088564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anuroctoxin, a new scorpion toxin of the alpha-KTx 6 subfamily, is highly selective for Kv1.3 over IKCa1 ion channels of human T lymphocytes.
    Bagdány M; Batista CV; Valdez-Cruz NA; Somodi S; Rodriguez de la Vega RC; Licea AF; Varga Z; Gáspár R; Possani LD; Panyi G
    Mol Pharmacol; 2005 Apr; 67(4):1034-44. PubMed ID: 15615696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators.
    Vennekamp J; Wulff H; Beeton C; Calabresi PA; Grissmer S; Hänsel W; Chandy KG
    Mol Pharmacol; 2004 Jun; 65(6):1364-74. PubMed ID: 15155830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels.
    Koo GC; Blake JT; Shah K; Staruch MJ; Dumont F; Wunderler D; Sanchez M; McManus OB; Sirotina-Meisher A; Fischer P; Boltz RC; Goetz MA; Baker R; Bao J; Kayser F; Rupprecht KM; Parsons WH; Tong XC; Ita IE; Pivnichny J; Vincent S; Cunningham P; Hora D; Feeney W; Kaczorowski G
    Cell Immunol; 1999 Nov; 197(2):99-107. PubMed ID: 10607427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block.
    Matheu MP; Beeton C; Garcia A; Chi V; Rangaraju S; Safrina O; Monaghan K; Uemura MI; Li D; Pal S; de la Maza LM; Monuki E; Flügel A; Pennington MW; Parker I; Chandy KG; Cahalan MD
    Immunity; 2008 Oct; 29(4):602-14. PubMed ID: 18835197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent Kv1.3 inhibitors from correolide-modification of the C18 position.
    Bao J; Miao S; Kayser F; Kotliar AJ; Baker RK; Doss GA; Felix JP; Bugianesi RM; Slaughter RS; Kaczorowski GJ; Garcia ML; Ha SN; Castonguay L; Koo GC; Shah K; Springer MS; Staruch MJ; Parsons WH; Rupprecht KM
    Bioorg Med Chem Lett; 2005 Jan; 15(2):447-51. PubMed ID: 15603971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphocyte calcium influx characteristics and their modulation by Kv1.3 and IKCa1 channel inhibitors in healthy pregnancy and preeclampsia.
    Toldi G; Stenczer B; Treszl A; Kollár S; Molvarec A; Tulassay T; Rigó J; Vásárhelyi B
    Am J Reprod Immunol; 2011 Feb; 65(2):154-63. PubMed ID: 20649894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity.
    Baell JB; Gable RW; Harvey AJ; Toovey N; Herzog T; Hänsel W; Wulff H
    J Med Chem; 2004 Apr; 47(9):2326-36. PubMed ID: 15084131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis.
    Beeton C; Wulff H; Barbaria J; Clot-Faybesse O; Pennington M; Bernard D; Cahalan MD; Chandy KG; Béraud E
    Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13942-7. PubMed ID: 11717451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.